BLUE Earnings Prediction
The chart below shows how BLUE performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BLUE sees a +8.90% change in stock price 10 days leading up to the earnings, and a -4.03% change 10 days following the report. On the earnings day itself, the stock moves by -3.60%. This data can give you a slight idea of what to expect for the next quarter's release.
BLUE Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
10.61M
-14.36%
-34.09%
Gross Margin
-11.02%
-195.00%
-86.19%
Operating Margin
-604.11%
-11.65%
10.04%
Net Margin
-573.01%
-1.01%
13.35%
EPS
-0.31
-53.03%
-26.19%
No Data Available
BLUE Earnings Analysis
bluebird bio, Inc. Common Stock Corporation (BLUE.O) Earnings Conference Call
Positive
Strong Foundation for Growth: We have built what we believe to be an unparalleled foundation over the past two years since our first FDA approval with a robust qualified treatment center network, proven access and reimbursement and demonstrated demand for our therapies from both patients and from providers.
Patient Start Growth: Since we reported our Q2 earnings in August, we have more than doubled patient starts from 27 to 57 across our portfolio.
Cost Reduction Strategy: We initiated steps to reduce our cash operating expenses by 20% in Q3 2025, and we've laid out a roadmap to financial stability and cash flow breakeven in the second half of next year should we accomplish our goal of securing additional cash resources.
Patient Start Progress: Today, we announced that 74 patient starts have been completed or scheduled to date in 2024 across our portfolio. Of that 74, 57 patient starts have been completed with an additional 17 starts scheduled through the rest of the year.
Future Patient Demand: We continue to see strong and sustained demand into the future, with 30 patient starts already scheduled in 2025.
Negative
Revenue Decline in Q3: In the third quarter, total revenue decreased to $10.6 million, down from $16.1 million in Q2.
R&D Expense Reduction: R&D expense was down $36.1 million year-over-year, indicating a shift in focus away from product development.
High Operating Expenses Outlook: Operating expenses are expected to remain high due to fixed costs associated with manufacturing and testing.
Cash Flow Break-Even Anticipation: The company anticipates a cash flow break-even in the second half of 2025, which may indicate ongoing financial challenges.
Patient Start Decline: The company reported a dip in patient starts from 57 in mid-August to 30 scheduled for 2025, reflecting potential issues in customer growth.
BLUE FAQs
How does BLUE typically perform around its earnings report dates?
Is bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BLUE Earning Call Sentiment
bluebird bio, Inc. (BLUE) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BLUE.O
-1%Positive
The earnings call shows mixed signals: while there's a positive outlook with steady demand and strong pull-through rates, the financial performance is weak with revenue decline and cash challenges. The reverse stock split proposal to regain NASDAQ compliance is neutral to negative. The Q&A reveals consistent manufacturing timelines and adequate capacity but lacks clarity on cash gap strategy. Overall, the sentiment is neutral as the positives and negatives balance out, with no major catalysts to drive significant stock price movement.